These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6130754)

  • 1. [Neurochemical aspects of parkinsonism. Review of the literature].
    De Mattos JP; Cechela C; Adams JG; De Lima JM
    Arq Neuropsiquiatr; 1982 Sep; 40(3):289-95. PubMed ID: 6130754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's disease: from brain homogenate to treatment.
    Hornykiewicz O
    Fed Proc; 1973 Feb; 32(2):183-90. PubMed ID: 4143953
    [No Abstract]   [Full Text] [Related]  

  • 3. [Biochemical bases of Parkinson disease].
    Colucci d'Amato C; Puccini A; Cristillo A; Vizioli R
    Recenti Prog Med; 1984 Oct; 75(10):889-901. PubMed ID: 6151219
    [No Abstract]   [Full Text] [Related]  

  • 4. CNS compensation to dopamine neuron loss in Parkinson's disease.
    Lloyd KG
    Adv Exp Med Biol; 1977; 90():255-66. PubMed ID: 930746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor.
    Fahn S; Libsch LR; Cutler RW
    J Neurol Sci; 1971 Dec; 14(4):427-55. PubMed ID: 5125758
    [No Abstract]   [Full Text] [Related]  

  • 6. [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy.
    Bokobza B; Ruberg M; Scatton B; Javoy-Agid F; Agid Y
    Eur J Pharmacol; 1984 Mar; 99(2-3):167-75. PubMed ID: 6734727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of tetanus toxin on transmitter release from substantia nigra and striatum in vitro.
    Collingridge GL; Collins GG; Davies J; James TA; Neal MJ; Tongroach P
    J Neurochem; 1980 Mar; 34(3):540-7. PubMed ID: 7354328
    [No Abstract]   [Full Text] [Related]  

  • 8. n-hexane induces parkinsonism in rodents.
    Pezzoli G; Ricciardi S; Masotto C; Mariani CB; Carenzi A
    Brain Res; 1990 Oct; 531(1-2):355-7. PubMed ID: 1705155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The biochemistry of the basal ganglia and Parkinson's disease.
    Curzon G
    Postgrad Med J; 1977 Dec; 53(626):719-25. PubMed ID: 24209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurochemistry of Parkinson's disease: relation between striatal and limbic dopamine.
    Price KS; Farley IJ; Hornykiewicz O
    Adv Biochem Psychopharmacol; 1978; 19():293-300. PubMed ID: 696462
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of chronically administered L-dopa in normal and lesioned cats.
    Langelier P; Roberge AG; Boucher R; Poirier LJ
    J Pharmacol Exp Ther; 1973 Oct; 187(1):15-26. PubMed ID: 4746324
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of a short period of vitamin E-deficient diet in the turnover of different neurotransmitters in substantia nigra and striatum of the rat.
    Castaño A; Herrera AJ; Cano J; Machado A
    Neuroscience; 1993 Mar; 53(1):179-85. PubMed ID: 7682297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical and pathological study of endogenous 1-benzyl-1,2,3,4-tetrahydroisoquinoline-induced parkinsonism in the mouse.
    Abe K; Taguchi K; Wasai T; Ren J; Utsunomiya I; Shinohara T; Miyatake T; Sano T
    Brain Res; 2001 Jul; 907(1-2):134-8. PubMed ID: 11430895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?
    Russ H; Mihatsch W; Gerlach M; Riederer P; Przuntek H
    Neurosci Lett; 1991 Feb; 123(1):115-8. PubMed ID: 1712088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased concentrations of 3-methoxy-4-hydroxyphenylethyl-eneglycol and homovanillic acid in rat brain after treatment with BE-2254 ("HEAT").
    Clineschmidt BV; Totaro JA; Pflueger AB; McGuffin JC
    J Pharm Pharmacol; 1975 Oct; 27(10):780-2. PubMed ID: 241795
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis.
    Date I; Felten DL; Felten SY
    Brain Res; 1990 Jun; 519(1-2):266-76. PubMed ID: 1975765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Striatonigral degeneration. Response to levodopa therapy with pathological and neurochemical correlation.
    Sharpe JA; Rewcastle NB; Lloyd KG; Hornykiewicz O; Hill M; Tasker RR
    J Neurol Sci; 1973 Jul; 19(3):275-86. PubMed ID: 4716845
    [No Abstract]   [Full Text] [Related]  

  • 18. Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model.
    Rai SN; Yadav SK; Singh D; Singh SP
    J Chem Neuroanat; 2016 Jan; 71():41-9. PubMed ID: 26686287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine release in substantia nigra?
    Korf J; Zieleman M; Westerink BH
    Nature; 1976 Mar; 260(5548):257-8. PubMed ID: 1256566
    [No Abstract]   [Full Text] [Related]  

  • 20. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
    Biggs CS; Starr MS
    Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.